Early-onset gout

被引:7
作者
Pascart, Tristan [1 ,3 ,4 ]
Ducoulombier, Vincent [1 ]
Jauffret, Charlotte [1 ,2 ]
机构
[1] Lille Catholic Univ, St Philibert Hosp, Dept Rheumatol, Lomme Les Lille, France
[2] Lille Catholic Univ, ETHICS Lab, EA7446, Lille, France
[3] Univ Lille, ULR 2694 METRICS, CERIM, Lille, France
[4] Hop St Philibert, Serv Rhumatol, rue Grand But, F-59160 Lomme Les Lille, France
关键词
Gout; Early-onset; Prevalence; Cardiovascular disease; Metabolic syndrome; RHEUMATOLOGY GUIDELINE; AMERICAN-COLLEGE; MANAGEMENT; POPULATION; PREVALENCE; ABCG2; RISK; HYPERURICEMIA; ASSOCIATION; VARIANTS;
D O I
10.1016/j.jbspin.2024.105704
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Early-onset gout (EOG) is characterized by the occurrence of the first symptoms of gout at an unusually young age, usually < 40 years. The aim of this review is to provide an overview of the epidemiology, clinical presentation and prognosis, association with comorbidities and specific management of EOG. A particularly high proportion of patients with EOG come from ethnic groups with stronger genetic factors, such as populations in the Pacific and Taiwan, who therefore have the highest prevalence of gout overall. The clinical presentation and severity of gout are broadly similar between EOG and common gout, although a longer disease duration exacerbates the disease, which more often tends to become polyarticular. Patients suffering from EOG develop metabolic comorbidities commonly associated with gout earlier in life, although those tend to be less frequent at the time of diagnosis. Some international guidelines recommend early treatment of EOG patients with urate-lowering therapies. (c) 2024 L'Auteur(s). Publie par Elsevier Masson SAS au nom de Societe franc,aise de rhumatologie. Cet article est publie en Open Access sous licence CC BY-NC-ND (http://creativecommons.org/licenses/bync-nd/4.0/).
引用
收藏
页数:6
相关论文
共 58 条
[21]   Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout [J].
Helget, Lindsay N. ;
O'Dell, James R. ;
Newcomb, Jeff A. ;
Androsenko, Maria ;
Brophy, Mary T. ;
Davis-Karim, Anne ;
England, Bryant R. ;
Ferguson, Ryan ;
Pillinger, Michael H. ;
Neogi, Tuhina ;
Palevsky, Paul M. ;
Wu, Hongsheng ;
Kramer, Bridget ;
Mikuls, Ted R. .
LANCET RHEUMATOLOGY, 2023, 5 (12) :e706-e706
[22]  
Hisatome I., 2020, Gout Uric Nucleic Acids, V44, P1
[23]  
Hui M, 2017, RHEUMATOLOGY, V56, P1056, DOI 10.1093/rheumatology/kex150
[24]   Aotearoa New Zealand Maori and Pacific Population-amplified Gout Risk Variants: CLNKIs a Separate Risk Gene at the SLC2A9 Locus [J].
Ji, Aichang ;
Shaukat, Amara ;
Takei, Riku ;
Bixley, Matthew ;
Cadzow, Murray ;
Topless, Ruth K. ;
Major, Tanya J. ;
Phipps-Green, Amanda ;
Merriman, Marilyn E. ;
Hindmarsh, Jennie Harre ;
Stamp, Lisa K. ;
Dalbeth, Nicola ;
Li, Changgui ;
Merriman, Tony R. .
JOURNAL OF RHEUMATOLOGY, 2021, 48 (11) :1736-1744
[25]   Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective [J].
Kapetanovic, Meliha C. ;
Hameed, Mohaned ;
Turkiewicz, Aleksandra ;
Neogi, Tuhina ;
Saxne, Tore ;
Jacobsson, Lennart ;
Englund, Martin .
RMD OPEN, 2016, 2 (02)
[26]   Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout [J].
Kawamura, Yusuke ;
Nakaoka, Hirofumi ;
Nakayama, Akiyoshi ;
Okada, Yukinori ;
Yamamoto, Ken ;
Higashino, Toshihide ;
Sakiyama, Masayuki ;
Shimizu, Toru ;
Ooyama, Hiroshi ;
Ooyama, Keiko ;
Nagase, Mitsuo ;
Hidaka, Yuji ;
Shirahama, Yuko ;
Hosomichi, Kazuyoshi ;
Nishida, Yuichiro ;
Shimoshikiryo, Ippei ;
Hishida, Asahi ;
Katsuura-Kamano, Sakurako ;
Shimizu, Seiko ;
Kawaguchi, Makoto ;
Uemura, Hirokazu ;
Ibusuki, Rie ;
Hara, Megumi ;
Naito, Mariko ;
Takao, Mikiya ;
Nakajima, Mayuko ;
Iwasawa, Satoko ;
Nakashima, Hiroshi ;
Ohnaka, Keizo ;
Nakamura, Takahiro ;
Stiburkova, Blanka ;
Merriman, Tony R. ;
Nakatochi, Masahiro ;
Ichihara, Sahoko ;
Yokota, Mitsuhiro ;
Takada, Tappei ;
Saitoh, Tatsuya ;
Kamatani, Yoichiro ;
Takahashi, Atsushi ;
Arisawa, Kokichi ;
Takezaki, Toshiro ;
Tanaka, Keitaro ;
Wakai, Kenji ;
Kubo, Michiaki ;
Hosoya, Tatsuo ;
Ichida, Kimiyoshi ;
Inoue, Ituro ;
Shinomiya, Nariyoshi ;
Matsuo, Hirotaka .
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (10) :1430-1437
[27]   Real-world treatment of gout and asymptomatic hyperuricemia: A cross-sectional study of Japanese health insurance claims data [J].
Koto, Ruriko ;
Nakajima, Akihiro ;
Horiuchi, Hideki ;
Yamanaka, Hisashi .
MODERN RHEUMATOLOGY, 2021, 31 (01) :261-269
[28]   Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study [J].
Kuo, Chang-Fu ;
Grainge, Matthew J. ;
Mallen, Christian ;
Zhang, Weiya ;
Doherty, Michael .
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (04) :661-667
[29]   Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout [J].
Laurent, Victor ;
Jauffret, Charlotte ;
Pacaud, Aurore ;
Ducoulombier, Vincent ;
Legrand, Julie ;
Verdun, Stephane ;
Norberciak, Laurene ;
Budzik, Jean-Francois ;
Pascart, Tristan .
RMD OPEN, 2023, 9 (04)
[30]   Clinical Characteristics of Early-Onset Gout in Outpatient Setting [J].
Li, Yan ;
Piranavan, Paramarajan ;
Sundaresan, Devi ;
Yood, Robert .
ACR OPEN RHEUMATOLOGY, 2019, 1 (07) :397-402